



Suggested Formula	Oseltamivir 15 mg/mL Oral Liquid (Suspension, 100 mL)	FIN	F 004 081
-------------------	---	-----	-----------

SUGGESTED FORMULATION

Ingredient Listing	Qty.	Unit	NDC #	Supplier	Lot Number	Expiry Date
Oseltamivir (75 mg) Capsules **	20	units				
Cherry (flavor)(artificial)	0.3	mL				
Ora-Blend SF (Sugar Free)	30.0	mL				
Ora-Blend SF (Sugar Free)	q.s. to 100.0	mL				

** Delivered as Oseltamivir Phosphate.

SPECIAL PREPARATORY CONSIDERATIONS

Ingredient-Specific Information

Light sensitive (protect from light whenever possible): *Oseltamivir*

Suggested Preparatory Guidelines

Non-Sterile Preparation Sterile Preparation

Processing Error / Testing Considerations: To account for processing error considerations during preparation, it is suggested to measure an additional **5 to 9%** of the required quantities of ingredients.

Special Instruction: Protective apparel, such as a lab coat, disposable gloves, eyewear and face-masks should always be worn.

This procedure requires the use of very small quantities of ingredients. All calculations and preparation techniques must be verified before dispensing the final product.



Suggested Formula	Oseltamivir 15 mg/mL Oral Liquid (Suspension, 100 mL)	FIN	F 004 081
-------------------	---	-----	-----------

SUGGESTED PREPARATION (for 100 mL)


Weigh and / or measure the following ingredients when appropriate:

Ingredient Listing	Qty.	Unit	Multiplication factor (*): ____	Processing Error	Qty. to measure
Oseltamivir (75 mg) Capsules ** §	20	units			
Cherry (flavor)(artificial)	0.3	mL			
Ora-Blend SF (Sugar Free)	30.0	mL			
Ora-Blend SF (Sugar Free)	q.s. to 100.0	mL			

* Takes into account increased batch size conversions and density conversions, if required.

§ Weigh / measure just prior to use.

** Delivered as Oseltamivir Phosphate.





Suggested Formula	Oseltamivir 15 mg/mL Oral Liquid (Suspension, 100 mL)	FIN	F 004 081
-------------------	---	-----	-----------

Preparatory Instruction

1. **Ingredient quantification (determine the actual quantity of Oseltamivir powder to weigh if accounting for processing error adjustments):**
 - A. Empty and weigh the contents of 22 x Oseltamivir (75 mg) Capsules. Record the total weight here: _____ g
 - B. Calculate the average weight of powder in each capsule:

Weight of powder from 22 capsules (from Step 1A):	_____ g
DIVIDED BY	
Number of capsules	22
EQUALS	
Average weight of powder from a single Oseltamivir (75 mg) capsule:	_____ g
 - C. Calculate the weight of powder equivalent to 20 capsules:

Average weight of powder from a single Oseltamivir (75 mg) capsule (from Step 1B):	_____ g
MULTIPLIED BY	
Number of capsules required:	20
EQUALS	
Weight of powder equivalent to 20 capsules:	_____ g
 - D. Calculate the weight of powder required *plus* processing error adjustments:

Weight of powder equivalent to 20 capsules (from Step 1C):	_____ g
MULTIPLIED BY	
Processing error adjustments (5 to 9%):	1.05 to 1.09
EQUALS	
Weight of powder required <i>plus</i> processing error adjustments:	_____ g
2. **Powder preparation:**
 - A. Triturate the contents of the 22 Oseltamivir (75 mg) capsules to form a fine, homogeneous powder.
 - B. Weigh the quantity of Oseltamivir (75 mg) capsule powder required for the batch (refer to Step 1D) and discard the remaining powder.



Suggested Formula	Oseltamivir 15 mg/mL Oral Liquid (Suspension, 100 mL)	FIN	F 004 081
3.	<p><u>Powder-liquid preparation:</u></p> <p>A. Levigate the Oseltamivir (75 mg) capsule powder (amount weighed in Step 2B) with Ora-Blend SF (Sugar Free) (30.0 mL <i>plus</i> processing error adjustments).</p> <p><u>End result:</u> Homogeneous liquid-like dispersion.</p> <p>B. Incrementally add the Cherry (flavor)(artificial) to the homogeneous liquid-like dispersion (Step 3A).</p> <p><u>End result:</u> Homogeneous liquid-like dispersion.</p>		
4.	<p><u>Filling to volume:</u></p> <p>A. Add additional Ora-Blend SF (Sugar Free) to the mixture (Step 3B) to fill to the required batch size (100.0 mL <i>plus</i> processing error adjustments).</p> <p><u>Specifications:</u> Continuously mix, using high-shear mixing techniques.</p> <p><u>End result:</u> Homogeneous liquid-like dispersion.</p>		
5.	<p><u>Product transfer:</u></p> <p>Transfer the final product into the specified dispensing container (see “Packaging requirements”).</p> <p><u>Note:</u> Continuously mix the final product during the transfer process into the recommended dispensing containers in order to maintain homogeneity.</p>		

SUGGESTED PRESENTATION

Estimated Beyond-Use Date	14 days, refrigerated.	Packaging Requirements	- Tight, amber glass bottle. - To be administered with a metered dose-measuring device	
Auxiliary Labels	1	Use as directed. Do not exceed prescribed dose.	6	Keep refrigerated. Do not freeze.
	2	May impair mental and/or physical ability. Use care when operating a car or machinery.	7	Consult your health care practitioner if any prescription or over-the-counter medications are currently being used or are prescribed for future use.
	3	Shake well before use.	8	Keep out of reach of children.
	4	Cap tightly after use.	9	Do not take with alcohol, sleep aids, tranquilizers or other CNS depressants.
	5	Protect from light.		
Pharmacist Instructions	Add any auxiliary labels specific to the API to the dispensing container as deemed necessary.			
Patient Instructions	Contact your pharmacist in the event of adverse reactions.			



Suggested Formula	Oseltamivir 15 mg/mL Oral Liquid (Suspension, 100 mL)	FIN	F 004 081
-------------------	---	-----	-----------

REFERENCES

1.	Suspensions. In: Allen, LV, Jr. <i>The Art, Science and Technology of Pharmaceutical Compounding Third Edition</i> . American Pharmaceutical Association; 2008: 209.
2.	Tamiflu. In: Canadian Pharmacists Association. <i>Compendium of Pharmacists and Specialties, 2009</i> . 2236.
3.	Oseltamivir Phosphate. In: Sweetman SC, ed. <i>Martindale: The Complete Drug Reference, 36th Edition</i> . London, England: The Pharmaceutical Press; 2009: 900.
4.	Oseltamivir (Monograph). In: O'Neil MJ. <i>The Merck Index 14th Edition</i> . Whitehouse Station, NJ: Merck & Co, Inc.; 2006: Monograph #6889.
5.	Oseltamivir Phosphate. In: Trissel LA. <i>Trissel's Stability of Compounded Formulations, 4th Edition</i> . American Pharmaceutical Association; 2009: 424.
6.	Oseltamivir Systemic. Thomson Micromedex. <i>USP DI – Drug Information for the Health Care Professional, 26th Edition</i> . Taunton, MA: US Pharmacopeial Convention, Inc; 2006: 2304.
7.	USP <795>. <i>United States Pharmacopeia XXXII / National Formulary 27</i> . Rockville, MD. US Pharmacopeial Convention, Inc. 2009: 314.

DISCLAIMER: MEDISCA NETWORK INC. & RÉSEAU MEDISCA NETWORK INC., HEREBY REFERRED TO AS 'THE NETWORK', HAVE PROVIDED THE FORMULA AND INSTRUCTIONS ABOVE AS A MODEL FOR EDUCATIONAL PURPOSES ONLY ON THE BASIS OF THE RECOGNIZED COMPENDIA AND TEXTS REFERENCED AT THE END OF THIS DOCUMENT. THE NETWORK TAKES NO RESPONSIBILITY FOR THE VALIDITY OR ACCURACY OF THIS INFORMATION OR FOR ITS SAFETY OR EFFECTIVENESS, NOR FOR ANY USE THEREOF, WHICH IS AT THE SOLE RISK OF THE LICENSED PHARMACIST. ADJUSTMENTS MAY BE NEEDED TO MEET SPECIFIC PATIENT NEEDS AND IN ACCORDANCE WITH A LICENSED PRESCRIBER'S PRESCRIPTION. THE PHARMACIST MUST EMPLOY APPROPRIATE TESTS TO DETERMINE THE STABILITY OF THIS SUGGESTED FORMULA. THE NETWORK CANNOT BE HELD LIABLE TO ANY PERSON OR ENTITY CONCERNING CLAIMS, LOSS, OR DAMAGE CAUSED BY, OR ALLEGED TO BE CAUSED BY, DIRECTLY OR INDIRECTLY, THE USE OR MISUSE OF THE INFORMATION CONTAINED IN THIS SUGGESTED FORMULA. IN ALL CASES IT IS THE RESPONSIBILITY OF THE LICENSED PHARMACIST TO KNOW THE LAW, TO COMPOUND ANY FINISHED PRODUCT AND TO DISPENSE THESE PRODUCTS IN ACCORDANCE WITH FEDERAL AND STATE LAW.